CollPlant Biotechnologies (CLGN) EBITDA (2017 - 2025)

CollPlant Biotechnologies has reported EBITDA for 9 years, with the latest figure at -$3.2 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 20.73% year-over-year to -$3.2 million; the trailing twelve-month figure through Dec 2025 stood at -$1.8 million (down 936.07% YoY), and the FY2025 full-year result was -$11.5 million, up 33.44% from the prior year.
• EBITDA for Q4 2025 stood at -$3.2 million, up from -$3.5 million in the prior quarter.
• The five-year high for EBITDA was $10.0 million in Q1 2021, with the low at -$5.1 million in Q4 2023.
• Historically, EBITDA has averaged -$579100.0 across 5 years, with a median of -$3.1 million in 2021.
• The largest YoY upside for EBITDA was 687.35% in 2021 against a maximum downside of 421625.89% in 2021.
• CollPlant Biotechnologies' EBITDA stood at -$3.8 million in 2021, then decreased by 22.92% to -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then climbed by 21.59% to -$4.0 million in 2024, then grew by 20.73% to -$3.2 million in 2025.
• The last three EBITDA figures came in at -$3.2 million (Q4 2025), -$3.5 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.